The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2016 | The differences in treating older versus younger CLL patients
Matthew Davids, MD from Dana-Farber Cancer Institute, Boston, MA outlines the differences in the treatment of older and younger patients. In older patients monotherapy with kinase inhibitors and venetoclax may be a suitable option. In younger patients doctors may have more ambitious goals, curing these patients or at least getting them into complete remission (CR). Multiple strategies could be explored either with combining novel agents with traditional chemoimmunotherapy, or using only a combination of novel agents. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
